- Conditions
- Lymphoma, Primary Effusion
- Interventions
- Daratumumab SC
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2035
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 913–936
of 4,776
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Myeloma
- Interventions
- Bortezomib, Dexamethasone, Lenalidomide, Cilta-cel, Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 743 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2036
- U.S. locations
- 19
- States / cities
- San Francisco, California • New Haven, Connecticut • Miami, Florida + 13 more
- Conditions
- Cognitive Impairment, Hematologic Malignancy
- Interventions
- Modified ketogenic diet using an exogenous ketogenic formula, Online cognitive training
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Multiple Myeloma
- Interventions
- CC-92480, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib, Elotuzumab, Isatuximab
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 424 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 16
- States / cities
- Denver, Colorado • Tampa, Florida • Atlanta, Georgia + 10 more
- Conditions
- Malignant Solid Tumor, Lymphoma
- Interventions
- RRx-001, Nivolumab
- Drug
- Lead sponsor
- EpicentRx, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Colorectal Cancer
- Interventions
- Regorafenib, Atezolizumab, Imprime PGG, Bevacizumab, Isatuximab, Selicrelumab, Idasanutlin, AB928, LOAd703
- Drug · Genetic
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 6
- States / cities
- Duarte, California • New Haven, Connecticut • Boston, Massachusetts + 2 more
- Conditions
- Lesion Skin, Seborrheic Keratosis, Skin Lesion, Benign Skin Tumor
- Interventions
- Nano-Pulse Stimulation (NPS)
- Device
- Lead sponsor
- Pulse Biosciences, Inc.
- Industry
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Edwards, Colorado • Coral Gables, Florida + 4 more
- Conditions
- Parathyroid Cancer, Primary Hyperparathyroidism, Pseudohypoparathyroidism, Inheritable Bone Diseases, Multiple Endocrine Neoplasia, Type 1
- Interventions
- Not listed
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 6 Months to 100 Years
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Weight Loss, Men, Lifestyle Risk Reduction, Cardiovascular Diseases, Obesity
- Interventions
- Self-guided lifestyle intervention
- Behavioral
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years to 35 Years · Male only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Lymphoma, Non-Hodgkin, Multiple Myeloma
- Interventions
- G-CSF and plerixafor
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 5
- States / cities
- Duarte, California • Beech Grove, Indiana • Rochester, New York + 2 more
- Conditions
- Multiple Myeloma
- Interventions
- Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone
- Drug
- Lead sponsor
- Oncotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- West Hollywood, California
- Conditions
- Multiple Myeloma
- Interventions
- CART-19 T cells
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Head and Neck Cancer, Dysphagia
- Interventions
- non- head and neck self reporting, head neck self reporting, provider reporting
- Other
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 100 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Rochester, Minnesota + 3 more
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- AGS-16C3F, Axitinib
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 20
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 16 more
- Conditions
- Oncology, MET Gene Amplification, NSCLC, MET Gene Mutation, Non Small Cell Lung Cancer
- Interventions
- Sym015
- Drug
- Lead sponsor
- Symphogen A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 10
- States / cities
- Aurora, Colorado • Chicago, Illinois • Indianapolis, Indiana + 6 more
- Conditions
- Breast Neoplasms
- Interventions
- Ultrasound- Virtual Touch Tissue Imaging Quantification
- Device
- Lead sponsor
- Heidelberg University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Youngstown, Ohio
- Conditions
- Multiple Myeloma
- Interventions
- TTI-622, Daratumumab Hyaluronidase-fihj
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Breast Cancer
- Interventions
- MM-302 Monotherapy, MM-302 in combination with trastuzumab, MM-302 in combination with trastuzumab q3w, MM-302 in combination with trastuzumab and cyclophosphamide
- Drug
- Lead sponsor
- Merrimack Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 5
- States / cities
- San Francisco, California • Indianapolis, Indiana • Boston, Massachusetts + 2 more
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
- Interventions
- CM-CS1 T-cell infusion
- Biological
- Lead sponsor
- Celyad Oncology SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Multiple Myeloma
- Interventions
- Thalidomide, Dexamethasone
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer, Lung Cancer, Multiple Myeloma, Ovarian Cancer, Acute Myelogenous Leukemia
- Interventions
- Web based survey
- Other
- Lead sponsor
- Carevive Systems, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 7
- States / cities
- New Haven, Connecticut • Evanston, Illinois • Chapel Hill, North Carolina + 4 more
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Lymphoma, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myeloproliferative Neoplasms, Myelofibrosis, Myelodysplasia, Refractory Anemia, High Risk Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Diffuse Large Cell Non Hodgkins Lymphoma, Lymphoblastic Lymphoma, Burkitt Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult, Multiple Myeloma, Juvenile Myelomonocytic Leukemia, Biphenotypic/Undifferentiated/Prolymphocytic Leukemias, MRD Positive Leukemia, Natural Killer Cell Malignancies, Acquired Bone Marrow Failure Syndromes
- Interventions
- HSCT with TBI Regimen, HSCT with Non-TBI Regimen
- Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Impotence, Prostate Cancer
- Interventions
- GPI 1485
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 40 Years to 69 Years · Male only
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • La Mesa, California • Stanford, California + 19 more
- Conditions
- Anemia
- Interventions
- Peginesatide
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Corpus Christi, Texas